Revised forecast
Fiscal year ending July 2026 · Full yearPrevious forecast published 13 March 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The company is moving toward business operations that emphasize profitability and capital efficiency. As a result of thoroughly reviewing sales and investment activities with a focus on profitability and expenses, it now expects to secure profits exceeding its initial plan.
| Item | Details |
|---|---|
| Net Sales | 67,000 million yen → 63,200 million yen（▲5.7%） |
| Operating profit | 2,000 million yen → 2,600 million yen（30.0%） |
| Ordinary income | 2,000 million yen → 2,400 million yen（20.0%） |
| Profit attributable to owners of the parent | 1,500 million yen → 1,950 million yen（30.0%） |
| Net income per share | 51.65 yen and sen → 67.14 yen and sen |
| Fiscal Period Covered | Fiscal year ending July 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 13 March 2026 |
| Previous-period results | Revenue: ¥65,260 million; operating profit: ¥2,367 million; ordinary profit: ¥2,553 million; net income attributable to owners of the parent: ¥368 million; earnings per share: ¥12.83 |
| Reason for the revision | The company is moving toward business operations that emphasize profitability and capital efficiency. As a result of thoroughly reviewing sales and investment activities with a focus on profitability and expenses, it now expects to secure profits exceeding its initial plan. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.As a result of emphasizing profitability and capital efficiency, thoroughly reviewing sales and investment activities with a focus on profitability, and rigorously reviewing expenses, the company now expects to secure profits exceeding its initial plan. In B2B, the company cited the new adoption of Pharma GABA by overseas manufacturers, while in B2C it cited sales of the Newmo series and new products.